title: [Successful treatment for advanced hepatocellular carcinoma by hepatic arterial infusion of CDDP powder as second-line chemotherapy].
abstract: A 72-year-old man with type C liver cirrhosis had suffered from hepatocellular carcinoma (HCC) since April, 2001. HCC spread diffusely all over the right lobe of his liver, and the serum alpha-fetoprotein (AFP) value increased up to 42,696 ng/ml in June of 2004. He was implanted with a port-catheter system, and hepatic arterial infusion chemotherapy (HAIC) using low-dose of CDDP and 5-FU was started. However, it was not effective and after 4 months, the serum AFP level increased up to 755,030 ng/ml, ascites appeared, and gastro-esophageal varices also spread. No definite metastasis was detected, then we started to second-line chemotherapy. He was then given HAIC using CDDP powder for intraarterial use (CDDP 50 mg/m(2)/20 min, monthly). After 3 courses, the serum AFP level decreased to 9 10 ng/ml, and abdominal CT revealed that the main tumor had regressed and ascites had disappeared. After one more course, the serum AFP value decreased to 8 ng/ml and complete response was achieved on abdominal CT imaging. There was no major complication related to the chemotherapy. HAIC for advanced HCC using LFP has been reported to achieve favorable results, but no other regimens have been proved to the standard for HCC. HAIC using CDDP powder for advanced HCC may be beneficial as the second-line chemotherapy.
authors.affiliation: Dept. of Gastroenterology, Kyoto First Red Cross Hospital.
authors.forename: Yasuyuki
authors.initials: Y
authors.lastname: Gen
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Kimura
authors.forename: Reiko
authors.initials: R
authors.lastname: Akitake
authors.forename: Aya
authors.initials: A
authors.lastname: Sakai
authors.forename: Akifumi
authors.initials: A
authors.lastname: Fukui
authors.forename: Toshitatsu
authors.initials: T
authors.lastname: Takao
authors.forename: Satoshi
authors.initials: S
authors.lastname: Ikezawa
authors.forename: Atsuhiro
authors.initials: A
authors.lastname: Masuda
authors.forename: Hidetaka
authors.initials: H
authors.lastname: Takashima
authors.forename: Eiji
authors.initials: E
authors.lastname: Funatsu
authors.forename: Hideki
authors.initials: H
authors.lastname: Nakamura
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Okuyama
authors.forename: Masahiro
authors.initials: M
authors.lastname: Arai
authors.forename: Nobuaki
authors.initials: N
authors.lastname: Yagi
authors.forename: Hiromu
authors.initials: H
authors.lastname: Kutsumi
authors.forename: Sotaro
authors.initials: S
authors.lastname: Fujimoto
authors.forename: Yoshito
authors.initials: Y
authors.lastname: Takeuchi
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D006528:Carcinoma, Hepatocellular / Q000097:blood / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage*; D006801:Humans; D015918:Infusion Pumps, Implantable; D007261:Infusions, Intra-Arterial; D008103:Liver Cirrhosis / Q000150:complications; D008113:Liver Neoplasms / Q000097:blood / Q000188:drug therapy*; D008297:Male; D011208:Powders; D000509:alpha-Fetoproteins / Q000032:analysis
chemical_list: D000970:Antineoplastic Agents; D011208:Powders; D000509:alpha-Fetoproteins; D002945:Cisplatin